MapLight Therapeutics (MPLT) vs Neurogene (NGNE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neurogene is the larger company by market cap ($530.3 million vs $508.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MPLT | NGNE |
|---|---|---|
| Share price | $9.15 | $26.50 |
| Market cap | $508.52M | $530.30M |
| 1-day change | -2.24% | +2.44% |
| YTD return | -47.91% | +28.64% |
| 1-year return | — | +2.59% |
| 5-year return | — | -81.65% |
| EPS (TTM) | $-6.25 | $-5.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.43 | $43.66 |
| 52-week low | $8.92 | $15.93 |
| Distance from 52-week high | -77.37% | -39.30% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +190.05% | +193.89% |
| Average volume | 851.70K | 247.13K |
| Shares outstanding | 52.85M | 20.01M |
| Employees | 133 | 131 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: MapLight Therapeutics in Health Care and Neurogene in Healthcare.
About MapLight Therapeutics
MPLT stock →MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 133 employees
About Neurogene
NGNE stock →Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Healthcare · Biotechnology · 131 employees
MPLT vs NGNE FAQ
Which is bigger, MapLight Therapeutics or Neurogene?
Neurogene (NGNE) is larger, with a market capitalization of $530.30M compared with $508.52M for MapLight Therapeutics (MPLT).
Are MapLight Therapeutics and Neurogene in the same industry?
No. MapLight Therapeutics is in the Health Care sector, while Neurogene is in Healthcare.